20618-1-AP

antibody from Proteintech Group

Targeting: FAM83A BJ-TSA-9, MGC14128

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

20618-1-AP

Provider

Proteintech Group

Product name

FAM83A antibody

Antibody type

Polyclonal

Description

FAM83A antibody (Cat. #20618-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, WB, ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma.

Liu H, Yao J, Liu Y, Wu L, Tan Z, Hu J, Chen S, Zhang X, Cheng S
Discover oncology 2024 Jun 24;15(1):242

---

High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma.

Fei W, Yan Y, Liu G, Peng B, Liu Y, Chen Q
PeerJ 2023;11:e16306

---

FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.

Zhou B, Zhou X, Zhan C, Jin M, Yan S
Journal of endocrinological investigation 2023 Jun;46(6):1115-1130

---

Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer.

Chen G, Liu Y, Su D, Qiu J, Long J, Zhao F, Tao J, Yang G, Huang H, Xiao J, Zhang T, Zhao Y
Cellular oncology (Dordrecht, Netherlands) 2023 Dec;46(6):1691-1708

---

Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.

Gao J, Hu J, Yu F, Wang C, Sheng D, Liu W, Hu A, Yu K, Xiao X, Kuang Y, Zacksenhaus E, Gajendran B, Ben-David Y
BMC cancer 2023 Apr 4;23(1):306

---

Aberrant epigenetic and transcriptional events associated with breast cancer risk.

Marino N, German R, Podicheti R, Rusch DB, Rockey P, Huang J, Sandusky GE, Temm CJ, Althouse S, Nephew KP, Nakshatri H, Liu J, Vode A, Cao S, Storniolo AMV
Clinical epigenetics 2022 Feb 9;14(1):21

---

FAM83A is a potential biomarker for breast cancer initiation.

Marino N, German R, Podicheti R, Rockey P, Sandusky GE, Temm CJ, Nakshatri H, Addison RJ, Selman B, Althouse SK, Storniolo AMV
Biomarker research 2022 Feb 19;10(1):8

---

FAM83A has a pro-tumor function in ovarian cancer by affecting the Akt/Wnt/β-catenin pathway.

Zhao J, Zhao F, Yang T, Tian S, Zhao M, Wang S, Yang X
Environmental toxicology 2022 Apr;37(4):695-707

---

Long non-coding RNA FEZF1-AS1 promotes rectal cancer progression by competitively binding miR-632 with FAM83A.

Xie R, Liu C, Liu L, Lu X, Tang G
Acta biochimica et biophysica Sinica 2022 Apr 25;54(4):452-462

---

FAM83A promotes proliferation and metastasis via Wnt/β-catenin signaling in head neck squamous cell carcinoma.

Ji H, Song H, Wang Z, Jiao P, Xu J, Li X, Du H, Wu H, Zhong Y
Journal of translational medicine 2021 Oct 12;19(1):423

---

Involvement of MicroRNA-1-FAM83A Axis Dysfunction in the Growth and Motility of Lung Cancer Cells.

Liu PJ, Chen YH, Tsai KW, Yeah HY, Yeh CY, Tu YT, Yang CY
International journal of molecular sciences 2020 Nov 22;21(22)

---

Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.

Liu C, Peng X, Li Y, Liu S, Hou R, Zhang Y, Zuo S, Liu Z, Luo R, Li L, Fang W
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Mar;123:109780